Assessment of immune responses to hepatitis A vaccination in children aged 1 and 2 years
dc.contributor.buuauthor | Çelebi, Solmaz | |
dc.contributor.buuauthor | Hacımustafaoğlu, Mustafa Kemal | |
dc.contributor.buuauthor | Albayrak, Yücehan | |
dc.contributor.buuauthor | Sinirtaş, Ayşe Melda | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Pediatri Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/ Mikrobiyoloji Anabilim Dalı. | tr_TR |
dc.contributor.scopusid | 7006095295 | tr_TR |
dc.contributor.scopusid | 6602154166 | tr_TR |
dc.contributor.scopusid | 36165377200 | tr_TR |
dc.contributor.scopusid | 54788212600 | tr_TR |
dc.date.accessioned | 2023-05-29T10:50:42Z | |
dc.date.available | 2023-05-29T10:50:42Z | |
dc.date.issued | 2013 | |
dc.description.abstract | Aim: Hepatitis A can be prevented by vaccination. The aim of this study was to determine seropositivity for hepatitis A before vaccination in healthy children 12 and 24 months of age and compare seroconversion rates after vaccination between these 2 groups. Materials and methods: Forty-nine children aged 1 year (Group 1) and 51 children aged 2 years (Group 2) were included in the study. Inactive hepatitis A vaccine (Avaxim, 80 antigenic subtypes, 0.5 mL) were administered to every child in 2 doses, 6 months apart. Anti-hepatitis A virus (HAV) IgG and IgM antibodies were detected by Architect HAVAb-IgG and HAVAb-IgM (Abbott, Wiesbaden, Germany) test kits. Results: Nine percent of the children were seropositive for anti-HAV IgG before vaccination. The seroconversion rate at 2 weeks was 34% and 44% in Group 1 and Group 2, respectively. At 4 weeks the seroconversion rate was 87.7% and 90.1% in Group 1 and Group 2, respectively. All of the children who completed the vaccination program were seropositive at 28 weeks (after the second dose). No serious adverse reaction was observed in any of the children. Conclusion: It was determined that Avaxim, including 80 antigen units, is safe and immunogenic in healthy children 12 and 24 months of age. | en_US |
dc.identifier.citation | Çelebi, S. vd. (2013). “Assessment of immune responses to hepatitis A vaccination in children aged 1 and 2 years”. Turkish Journal of Medical Sciences, 43(4), 617-624. | tr_TR |
dc.identifier.endpage | 624 | tr_TR |
dc.identifier.issn | 1300-0144 | |
dc.identifier.issn | 1303-6165 | |
dc.identifier.issue | 4 | tr_TR |
dc.identifier.scopus | 2-s2.0-84880940153 | tr_TR |
dc.identifier.startpage | 617 | tr_TR |
dc.identifier.uri | https://doi.org/10.3906/sag-1206-99 | |
dc.identifier.uri | https://journals.tubitak.gov.tr/medical/vol43/iss4/22/ | |
dc.identifier.uri | http://hdl.handle.net/11452/32855 | |
dc.identifier.volume | 43 | tr_TR |
dc.identifier.wos | 000323609800022 | tr_TR |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | TÜBİTAK | tr_TR |
dc.relation.journal | Turkish Journal of Medical Sciences | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | General & internal medicine | en_US |
dc.subject | Hepatitis A vaccine | en_US |
dc.subject | Seroprevalence | en_US |
dc.subject | Safety | en_US |
dc.subject | Immunogenicity | en_US |
dc.subject | Children | en_US |
dc.subject | Maternal antibody | en_US |
dc.subject | Immunogenicity | en_US |
dc.subject | Seroprevalence | en_US |
dc.subject | Infants | en_US |
dc.subject | Safety | en_US |
dc.subject | Need | en_US |
dc.subject.emtree | Hepatitis A vaccine | en_US |
dc.subject.emtree | Hepatitis antibody | en_US |
dc.subject.emtree | Immunoglobulin G antibody | en_US |
dc.subject.emtree | Immunoglobulin M antibody | en_US |
dc.subject.emtree | Abdominal discomfort | en_US |
dc.subject.emtree | Adverse outcome | en_US |
dc.subject.emtree | Arthralgia | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Child | en_US |
dc.subject.emtree | Child health care | en_US |
dc.subject.emtree | Clinical assessment | en_US |
dc.subject.emtree | Clinical effectiveness | en_US |
dc.subject.emtree | Clinical trial | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Drug safety | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Gastrointestinal symptom | en_US |
dc.subject.emtree | Headache | en_US |
dc.subject.emtree | Hepatitis A | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Human experiment | en_US |
dc.subject.emtree | Hyperemia | en_US |
dc.subject.emtree | Immune response | en_US |
dc.subject.emtree | Immunogenicity | en_US |
dc.subject.emtree | Infant | en_US |
dc.subject.emtree | Infection prevention | en_US |
dc.subject.emtree | Injection site erythema | en_US |
dc.subject.emtree | Injection site induration | en_US |
dc.subject.emtree | Injection site pain | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Myalgia | en_US |
dc.subject.emtree | Normal human | en_US |
dc.subject.emtree | Preschool child | en_US |
dc.subject.emtree | Seroconversion | en_US |
dc.subject.emtree | Sex difference | en_US |
dc.subject.emtree | Systemic disease | en_US |
dc.subject.emtree | Treatment duration | en_US |
dc.subject.emtree | Vaccination | en_US |
dc.subject.scopus | Hepatitis A; Vaccination; Marginal Structural Models | en_US |
dc.subject.wos | Medicine, general & internal | en_US |
dc.title | Assessment of immune responses to hepatitis A vaccination in children aged 1 and 2 years | en_US |
dc.type | Article | |
dc.wos.quartile | Q3 | en_US |